

TB Laboratory Testing and Case Studies

September 26, 2018

Rebecca Kramer, Microbiologist, MDHHS

Angie Schooley, Mycobacteriology Supervisor, MDHHS

James Sunstrum, M.D.



• Prevent Disease • Promote Wellness • Improve Quality of Life •

Learning Objectives

- Review the cascade of laboratory tests a clinician may order to diagnose TB disease
- Integrate molecular assays with culture results
- Discuss the use of TB genotyping and Whole genome sequencing (WGS)
- Demonstrate the proper use of TB diagnostic tests using 3 sample cases of TB disease (*easy, medium & difficult*)



• Prevent Disease • Promote Wellness • Improve Quality of Life •

2

Disclosures

- None



◦ Prevent Disease ◦ Promote Wellness ◦ Improve Quality of Life ◦

3

TB Testing - What Do All the Words Mean?




NAA culture Amplification **MGIT** Genotypic **WGS**
MTD **16 S Sequencing** Susceptibility
Smear Phenotypic **Molecular** mutation
HPLC MALDI-Tof Gene Xpert
MDDR **NAAT** Genotyping



◦ Prevent Disease ◦ Promote Wellness ◦ Improve Quality of Life ◦

4

Status of the Tuberculosis Problem in 2014



Prevent Disease • Promote Well-being

Does this patient have TB disease?

Clinical Clues

- Cough > 2 weeks
- Fever > 2 weeks
- Exposure to TB
- Chronic immune suppression
- Endemic country
- Abnormal physical exam



Laboratory Tests

- PPD
- IGRA
- Sputum studies:
 - AFB Cultures
 - Molecular studies
- X-rays
- Biopsies



Quality of Life



Mycobacterial Examination



- **See the "Bugs"**
Specimen collection, decontamination, acid-fast bacilli (AFB) smears
- **Multiply the "Bugs"**
Nucleic acid amplification test
- **Grow the "Bugs"**
Mycobacterial culture, identification, and drug susceptibility testing
TB genotyping / WGS



TB is Difficult to Diagnose



High Accuracy for Diagnosis of HIV in Contrast to TB DISEASE





TB Specimens

- Sputum, Pulmonary aspiration
- Tissues, Body fluids (CSF, pleural, peritoneal), etc.
- All persons suspected of TB disease should have sputum cultured
- Early morning specimens have the highest yield of AFB
- Collect at least 3 consecutive specimens at 8-24 hour intervals
- Recommended volume for testing is 3-7 ml, less may compromise the recovery of AFB




How Many Tests!



Acid Fast Microscopy- "**See the Bugs**"

- Least sensitive of all AFB Tests / first result available
- Requires 10,000 AFB/ml for a slide to be positive
- Positive slide cannot determine AFB viability or TB vs NTM (Non tuberculosis Mycobacterium)



Auramine-O staining of AFB under Fluorescence Microscopy



Ziehl-Neelson (ZN) smear

Nucleic Acid Amplification Test (NAAT) or PCR

"Multiply the Bugs"



Available NAA Testing Systems

- Gene XPERT



FDA approved cartridge based NAAT that can detect the presence of *M. tuberculosis* complex DNA and resistance to Rifampicin from sputum

- Quant Studio




Non FDA approved real time PCR that can detect *M. tuberculosis* complex and *M. avium* complex from both respiratory and non-respiratory specimens (developed by Wadsworth, validated at MDHHS)

- MTD



FDA approved kit by Hologic that detects the presence of *M. tuberculosis* complex rRNA from respiratory specimens

GenExpert Assay Procedure for the MTB/RIF Test




Limitations of NAAT

- NAAT are intended for initial diagnosis only
- A negative test does not exclude the possibility of culturing MTBC
- May remain positive during and after TB treatment
- Inhibitors may be present that affect amplification



AFB Culture "Grow the Bugs"

- More sensitive than AFB smear, only 10 AFB/ml can produce a positive result
- Culture may be positive if the smear was negative
- Rapid broth system normally positive within 1-2 weeks
- Requires 6 weeks to report culture as negative



◦ Prevent Disease ◦ Promote Wellness ◦ Improve Quality of Life ◦

17

Mycobacterium Identification by Culture Based Methods (Which Tools to Use)



- HPLC: High Performance Liquid Chromatography
- MALDI-TOF: Matrix-Assisted Laser Desorption Ionization - Time of Flight
- Accuprobe: *M. tuberculosis* cplx., *M. avium* cplx., *M. kansasii*, *M. gordonae*
- 16S sequencing
- Conventional biochemical testing



◦ Prevent Disease ◦ Promote Wellness ◦ Improve Quality of Life ◦

18

MALDI-TOF / HPLC /Accuprobe



- Matrix-Assisted Laser Desorption Ionization - Time of Flight
- Extraction time ~2 hour
- Run time on the instrument approx. 1 minute



- High Performance Liquid Chromatography
- Extraction time ~2 hours
- Run time per specimen is ~15 minutes



- *M. tuberculosis complex*
- *M. avium complex*
- *M. kansasii*
- *M. goodii*



• Prevent Disease • Promote Wellness • Improve Quality of Life •

19

Primary TB Antibiotics

Most results are available within 7-14 days of *M. tuberculosis* complex Identification

- Isoniazid
- Rifampin
- Ethambutol
- Pyrazinamide



• Prevent Disease • Promote Wellness • Improve Quality of Life •

20

Molecular Detection of TB Drug Resistance (MDDR) CDC

- Rapid testing for DNA sequences associated with 1st and 2nd line drug resistance, results in 2-4 days
- NAAT (+) sputum sediment or growth based culture isolates, only requested by state health lab
- Submission criteria:
 - ✓ Known Rifampin resistance
 - ✓ Known MDR
 - ✓ High risk of Rifampin resistance or MDR-TB (e.g. previous TB, MDR-TB contact, foreign born)
 - ✓ High profile patient (e.g. daycare worker, nurse)
 - ✓ Mixed or non-viable culture
 - ✓ Adverse reaction (e.g. RIF allergy)



21

Why Genotyping?

- Confirm epidemiologic links
- Detect unsuspected transmission
- Outbreaks detected earlier; controlled more rapidly
- Detect or confirm false positive cultures
- With WGS data, detect drug resistance/susceptibility



• Prevent Disease • Promote Wellness • Improve Quality of Life •

22

TB Genotyping and Michigan



- 2003 & 2008 - Michigan & California awarded contract for genotyping on 4500 isolates each
- 2013 - Michigan awarded sole contract for 9000 isolates
- 2018 - Michigan awarded contract for genotyping and WGS on 9000 isolates




Prevent Disease • Promote Wellness • Improve Quality of Life •

23

Isolate Receipt & DNA Extraction

- Confirmed cultures are received and opened in a BSL3 lab
- Specimens are heat inactivated before removal from the BSL3
- DNA extracted via Bead Beater Homogenizer




Prevent Disease • Promote Wellness • Improve Quality of Life •


24

Genotyping Methods - Spoligotyping

- Variability in direct repeat region
- Direct repeats separated by unique "spacer" sequences
- 43 spacer sequences



Genotyping Methods – MIRU-VNTR



- PCR reactions amplify DNA at 24 different loci
- Capillary Electrophoresis
- Electropherograms analyzed
- Results uploaded to National TB Website

Genotype Reporting

- Results uploaded to TBGIMS National Database, clustered and compared to other isolates both within states and across the US

SpoligoType	MIRU	MIRU2	State Cluster	State Cluster Name2	Genotyping Lineage
000000000003771	223325173533	445644423328	MI_0016	MI_0016_003	G00012 East Asian (L2)



• Prevent Disease • Promote Wellness • Improve Quality of Life •

27


Whole Genome Sequencing

- Reveals complete genetic make-up of an organism at base-pair level
- Detect single nucleotide variants, insertions, deletions, structural variants, etc.
- TB Genome = 4.5 million base pairs



• Prevent Disease • Promote Wellness • Improve Quality of Life •

28



WGS Subtyping Analysis


- SNP (single nucleotide polymorphisms). Compares sequences to an established reference genome.

Reference genome: ACTTGCA

Isolate 1	ACTTGCA
Isolate 2	ACTTGCA
Isolate 3	ACTCGCA
Isolate 4	AGTTGCA
Isolate 5	GCTTGGA

- Results are displayed on dendrograms

- Bioinformatics needed to handle data
- Data is permanent, compatible with future technologies, will never be outdated




WGS and the Future!



- Improved Epi Links
- Faster ID
- Drug Susceptibility


3 Sample Cases




Michigan Department of Health & Human Services
Bureau of Laboratories

Prevent Disease • Promote Wellness • Improve Quality of Life

33

 The JAMA Network **Case #1 EASY**

From: **Current Approaches to Tuberculosis in the United States** JAMA. 2012;308(3):283-289. doi:10.1001/jama.2012.7505



Admission chest radiograph showing bilateral lung infiltrates with prominence in the right upper lobe and lingula of the left lung.

Michigan Department of Health & Human Services
Bureau of Laboratories

Copyright © 2012 American Medical Association. All rights reserved.

34

Case 1

- 50 yr male, cough for 2 months
- History of TB exposure 5 years ago. Never treated for latent TB
- HIV negative



◦ Prevent Disease ◦ Promote Wellness ◦ Improve Quality of Life ◦

35

APRIL 2019 "EASY" CASE					1 TB suspected	2 Sputum PPD or IGRA
3 AFB smear positive	4 PPD 15 mm	5 NAAT positive	6 INH, RIF, PZA, EMB	7	8	9
10	11	12 AFB in broth DNA probe+	13	14	15	16
17	18	19	20	21	22 Drug susceptibility	23
24	25	26 DNA genotype	27	28	29	30




36

#2 Case MEDIUM

57 yr male sick for 2 months

- Routine cultures negative
- No improvement
- Bronchoscopy AFB smear negative
- HIV +
- CD4 478 cells/mm³




APRIL 2019 "MEDIUM" CASE					1 HIV+ TB suspected	2 Sputum PPD or IGRA
3 AFB smear negative	4 PPD o mm 2 nd smear negative	5	6 IGRA negative	7 NAAT positive	8 INH, RIF, PZA, EMB	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25 AFB in broth, DNA probe +	26	27	28	29	30



Case #3 DIFFICULT

- Patient from Africa
- History of 3 prior episodes of pulmonary TB
- Coughing, sick again


#3 case MDR suspect




APRIL 2019 "DIFFICULT" CASE

3	4	5	6	7	1	2
AFB smear positive	IGRA positive	NAAT positive	INH, RIF, PZA, EMB ???		MDR-TB suspected	Sputum; IGRA
10	MDR regimen started	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30


41



02/01/2012 15:09 FAX 4046395491 CDC-TB-LAB
002/002



Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention (NCHSTP)
Division of Tuberculosis Elimination (DTBE)
Mycobacteriology Laboratory Branch
Reference Laboratory



Report Status: Interim

CLIA ID # 11D0668319

Original Submitter:

Submitter to CDC:

Michigan Dept. of Community Health / Labs

Angle Schooley/ Lab
Peter Davidson/ Program

CDC Specimen ID: [redacted]

Specimen: M. tuberculosis complex isolate

Medium: MGIT

Date Collected: 1/17/2012

Date Received: 1/31/2012

Date Reported: 2/1/2012

Patient: [redacted]

Submitter Specimen Identifiers: [redacted]

Results for Molecular Detection of Drug Resistance; Conventional Drug Susceptibility Test in progress.

Locus (region) examined*	Result	Interpretation (based on in-house evaluation of 254 clinical isolates)
rpoB (RRDR)	Mutation: TGG>TTG; Ser531Leu	Rifampin resistant. (100% of isolates in our in-house evaluation of 254 clinical isolates with this mutation are RMP-R.)
INH (promoter)	No mutation	Isoniazid resistant. (100% of isolates in our in-house evaluation of 254 clinical isolates with this mutation are INH-R.)
katG (acr315 codon)	Mutation: AGC>ACC; Ser315Ile	Probably Ethambutol resistant. (84% of isolates in our in-house evaluation of 254 clinical isolates with this mutation are EMB-R.)
ermB (Me336, C1y40)	Mutation: GAC>GCC; Asp354Asp	Probably Ethambutol resistant. (84% of isolates in our in-house evaluation of 254 clinical isolates with this mutation are EMB-R.)
pncA (promoter, coding region)	No mutation	Cannot rule out PZA resistance.
gyrA (QRDR)	No mutation	Cannot rule out fluoroquinolone resistance. (88% of FO-R isolates in our in-house evaluation of 254 clinical isolates have a mutation at this locus.)
rrs (1400 region)	No mutation	Cannot rule out resistance to injectable drugs (kanamycin, capreomycin, amikacin). (In our in-house evaluation of 254 clinical isolates: <ul style="list-style-type: none"> • 28% of AMK-R isolates have a mutation in the rrs locus; • 28% of KAN-R isolates have a mutation in the rrs locus; an additional 29% of KAN-R isolates have a mutation in the eis locus;
eis (promoter)	No mutation	
fyA (entire ORF)	No mutation	• 46% of CAP-R isolates have a mutation in the rrs locus; an additional 5% of CAP-R isolates have a mutation in the fyA locus.)

*A negative results (e.g., no mutation) does not rule out contributory mutations present elsewhere in the genome.

Testing performed using in-house developed assays.

MDHHS Lab Confirmation of 2nd Line Drugs

INH	R
Rifampin	R
PZA	R
Ethambutol	R
Ofloxacin	S
Ethionamide	R
Streptomycin	S
Kanamycin	S
Amikacin	S
Capreomycin	S
Cycloserine	S
PAS	S

IN CONCLUSION



- **See** the bugs [AFB microscopy]
- **Multiply** the bugs [NAATs]
- **Grow** the bugs / **Kill** the bugs [cultures]
- **Track** the bugs

Used separately, Molecular (genotypic) and growth based testing (phenotypic) are imperfect, used together, the accuracy and speed of detection of *Mycobacterium tuberculosis* and drug resistance is greatly improved



• Prevent Disease • Promote Wellness • Improve Quality of Life •

45



46